Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy.
Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy.
复制标题
作者：
尽管肿瘤免疫治疗在各种肿瘤中取得了巨大的成就，但肿瘤的异质性和耐药性仍然困扰着患者和临床研究人员。特别是，免疫相关不良事件的发生迫使患者停止癌症免疫治疗。因此，优化肿瘤免疫治疗，提高免疫治疗效果已迫在眉睫。随着测序技术的迭代，微生物组作为体内的第二组基因组，已被证明参与免疫和新陈代谢。越来越多的研究正在逐渐将视角转向肠道微生物区系和癌症免疫治疗。肠道微生物区系在免疫治疗中重新激活和调节免疫细胞，有望成为预测免疫疗效的生物标志物。靶向改善肠道微生物区系可增强抗肿瘤免疫。这一优势有利于控制相关不良症状，扩大癌症免疫治疗受益人群。这一发现可以帮助临床医生全面评估肿瘤筛查和肿瘤治疗的效果。因此，肠道微生物区系与癌症免疫治疗的创新结合有望成为增强个性化免疫反应的积极策略。近年来，肿瘤免疫治疗已成为解决实体瘤的突破性方法。它使用免疫检查点抑制剂来干扰肿瘤的免疫逃逸，以协调抗肿瘤治疗。然而，免疫治疗有个体化的应答率。此外，免疫相关不良事件和耐药性仍是亟待解决的问题，这可能与免疫检查点抑制剂导致的免疫失衡有关。微生物组的研究已经充分揭示了微生物组与宿主之间的代谢免疫相互作用关系。令人惊讶的是，测序技术进一步证明，肠道微生物区系可以有效干预肿瘤免疫治疗，降低不良事件的发生率。因此，肠道微生物区系干预下的肿瘤免疫治疗创新性地拓宽了抗肿瘤的视野，有望成为增强个体化反应的积极策略。
Despite the great achievements of cancer immunotherapy in a variety of tumors, tumor heterogeneity and drug resistance still plague patients and clinical researchers. In particular, the occurrence of immune-related adverse events forces patients to discontinue cancer immunotherapy. Therefore, it is urgent to optimize cancer immunotherapy and improve the efficacy of immunotherapy. With the iteration of sequencing technology, the microbiome, as the second set of genomes in the body, has been proven to be involved in immunity and metabolism. More and more studies are gradually shifting the perspective to the intestinal microbiota and cancer immunotherapy. The intestinal microbiota reactivates and modulates immune cells in immunotherapy and is expected to become a biomarker for predicting immune efficacy. Targeting to improve the intestinal microbiota can enhance anti-tumor immunity. This advantage is beneficial to control related adverse symptoms and expand the beneficiary population of cancer immunotherapy. This finding can help clinicians comprehensively evaluate the effect of tumor screening and tumor treatment. Therefore, the innovative combination of gut microbiota and cancer immunotherapy is expected to be an active strategy to enhance individualized immune responses. In recent years, cancer immunotherapy has become a breakthrough method to solve solid tumors. It uses immune checkpoint inhibitors to interfere with tumor immune escape to coordinate anti-tumor therapy. However, immunotherapy has an individualized response rate. Moreover, immune-related adverse events and drug resistance are still urgent issues that need to be resolved, which may be attributed to the immune imbalance caused by immune checkpoint inhibitors. Microbiome research has fully revealed the metabolic-immune interaction relationship between the microbiome and the host. Surprisingly, sequencing technology further proved that intestinal microbiota could effectively intervene in tumor immunotherapy and reduce the incidence of adverse events. Therefore, cancer immunotherapy under the intervention of intestinal microbiota has innovatively broadened the anti-tumor landscape and is expected to become an active strategy to enhance individualized responses.
登录
查看更多内容
影响因子：
5.1
作者：
Bajaj JS;Shamsaddini A;Fagan A;Sterling RK;Gavis E;Khoruts A;Fuchs M;Lee H;Sikaroodi M;Gillevet PM
通讯作者：
Gillevet PM
影响因子：
82.9
作者：
Baruch, Kuti;Deczkowska, Aleksandra;Schwartz, Michal
通讯作者：
Schwartz, Michal
影响因子：
23.4
作者：
Derosa, Lisa;Routy, Bertrand;Zitvogel, Laurence
通讯作者：
Zitvogel, Laurence
影响因子：
51.1
作者：
da Silva, Ines Pires;Ahmed, Tasnia;Long, Georgina V.
通讯作者：
Long, Georgina V.
DOI：
10.3390/molecules26082278
发表时间：
2021-04-14
期刊：
Molecules (Basel, Switzerland)
影响因子：
--
作者：
Derakhshani A;Rostami Z;Safarpour H;Shadbad MA;Nourbakhsh NS;Argentiero A;Taefehshokr S;Tabrizi NJ;Kooshkaki O;Astamal RV;Singh PK;Taefehshokr N;Alizadeh N;Silvestris N;Baradaran B
通讯作者：
Baradaran B